Everbright: Maintains the "Buy" rating for ASCLETIS-B. ASC47 combined with semaglutide shows superior effects.

Everbright released a research report stating that ASCLETIS-B (01672) is actively laying out its strategies in the MASH and weight loss sectors, and its progress is among the best in the country. Considering the company's effective control over various expenses, the net income forecast for 2024-2025 has been adjusted to -0.261/-0.313 billion yuan (previously -0.284/-0.34 billion yuan), and a new net income forecast for 2026 is -0.322 billion yuan, maintaining a "Buy" rating. The company released experimental data on the weight loss and muscle gain treatment drug ASC47 combined with semaglutide in obese mice; this drug is a fat-targeting, once-a-month subcutaneous injection of a thyroid hormone receptor β agonist.

Sina Hong Kong StocksDec 24 03:33 ET

Hong Kong stocks fluctuated | China-Affiliated Brokerage surged rapidly in the afternoon, with Institutions stating that multiple Bullish factors are catalyzing the Brokerage market, indicating that the Sector is expected to see both performance and valua

China-Affiliated Brokerage stocks surged rapidly in the afternoon. As of the time of publication, Guolian (01456) rose by 4.09%, trading at 4.84 Hong Kong dollars; China Merchants (06099) rose by 2.96%, trading at 16.02 Hong Kong dollars; Everbright (06178) rose by 1.1%, trading at 8.24 Hong Kong dollars; SWHY (06806) rose by 0.83%, trading at 2.44 Hong Kong dollars.

Zhitong FinanceDec 17 00:43 ET

China Court Rules Litigation Case Against Jin Tong Ling to Proceed; Shares Fall 8%

MT NewswiresDec 16 22:56 ET

Everbright (06178) received a complaint and civil ruling.

Everbright Securities (06178) announced that the company received a notice from the Intermediate People's Court of Nanjing City, Jiangsu Province on December 16, 2024...

Zhitong FinanceDec 16 18:51 ET

Everbright: Maintains TONGCHENGTRAVEL 'Buy' rating, with Q3 2024 performance showing high growth.

Everbright Securities released a research report stating that TONGCHENGTRAVEL (00780) maintains a "Buy" rating, and essentially keeps the company's revenue projections for 2024-2026 at 17.263, 20.195, and 23.134 billion yuan respectively, with adjusted net income forecasts at 2.74, 3.252, and 3.872 billion yuan. Everbright Securities' main points are as follows: In Q3 2024, performance remains high, with core OTA profit margins increasing: In Q3 2024, the company's revenue was 4.991 billion yuan, up 51% year-on-year; achieving an adjusted net income of 0.91 billion yuan, up 46.6% year-on-year; both revenue and adjusted net income exceeded the company's previous guidance.

Sina Hong Kong stocks.Dec 15 21:28 ET

Market Chatter: Chinese Brokerages Shuttering Branches to Remain Competitive

MT NewswiresDec 13 02:06 ET